UDENYCA® is designed to help deliver optimal care and support clinical outcomes

An FDA-approved biosimilar to Neulasta® (pegfilgrastim)

UDENYCA® offers cost savings, reliable manufacturing, patient support, and more.

Video Play Button
Atom Icon
Proving the value
of biosimilars
UDENYCA® delivers high-quality treatment and the reliable outcomes you expect, but with 35% cost savings per dose vs Neulasta®.*1
Discover the value of UDENYCA®
Badge Icon
UDENYCA® was demonstrated to be highly similar to Neulasta®, with no clinically meaningful differences.2,3
View the proven biosimilarity
Syringe Icon
Dosing & administration
UDENYCA® is dosed identically to Neulasta® prefilled syringe.2,3
Get dosing & administration information
*Savings per dose based on WAC of UDENYCA® vs Neulasta® as of July 2022.

Comprehensive patient support services

UDENYCA Solutions provides a suite of patient support services, programs, and industry-leading electronic services designed to assist with patient access.


Out-of-pocket (OOP) cost for each UDENYCA® dose*

*Must be prescribed UDENYCA® (pegfilgrastim-cbqv) for a medically appropriate use. Must have commercial health insurance that covers the medication costs of UDENYCA®. Must not be covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicaid, Medicare Advantage, Medicare Part D, Veterans Affairs, the Department of Defense, or TRICARE. Must not seek co-pay assistance amount received from Coherus from any third-party payers, including flexible spending accounts or healthcare savings accounts.

Note: The UDENYCA Solutions Co-Pay Savings Program covers ONLY the cost of UDENYCA® and does not cover any administration or office visit costs.

Stay informed

Receive occasional emails about UDENYCA®, reimbursement, and support services.


References: 1. Data on file. Coherus BioSciences, Inc.; 2023. 2. UDENYCA® (pegfilgrastim-cbqv) Prescribing Information. Redwood City, CA: Coherus BioSciences, Inc.; 2023. 3. Neulasta® (pegfilgrastim) Prescribing Information. Thousand Oaks, CA: Amgen Inc.; 2021.